Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Endo International announced that one of its operating companies, Par Pharmaceutical, has begun shipping dexlansoprazole 30 mg capsules, a generic version of Takeda's Dexilant®.
read more
The challenge of processing complex oral solid dosage, from formulation design to scale-up and manufacturing is driving more drug developers to outsource these steps, according to a report by Roots Analysis.
read more
TekniPlex Healthcare, is building a 200,000-square-foot manufacturing plant in Madison, Wisconsin – the second TekniPlex Healthcare facility in the city.
read more
Mangoceuticals, a men’s health and wellness company, announced the upcoming release of its second Mango erectile dysfunction (ED) product, which uses its existing custom compound alongside Sildenafil, the active ingredient found in Viagra™.
read more
The veterinary active pharmaceutical ingredient (API) market in terms of revenue was estimated to be worth $5.2B in 2023 and is poised to reach $7.1B by 2028, growing at a CAGR of 6.5% from 2023 to 2028 according to a report by MarketsandMarkets™.
read more
The Europe spirulina market is expected to reach $156.61M by 2030, at a CAGR of 13.3% from 2023 to 2030, while in terms of volume, the market is expected to reach $8,308.8 tons by 2030, at a CAGR of 7.5% from 2023 to 2030, according to a report by Research & Markets.
read more
The Lubrizol Corporation announced the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The license allows Welton to use the Apisolex excipient worldwide to develop and commercialize a novel formulation of SN-38 to treat colorectal and associated gastro-intestinal cancers.
read more
The FDA issued draft guidance for industry titled “Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Food, Drug and Cosmetic Act.”
read more
The global coronary artery disease (CAD) market will reach $38.17B in 2028 from $22.94B in 2022, growing at a CAGR of 8.86%, according to a report by Research & Markets.
read more
The “smart pills” market –generating $600M revenue in 2023, is poised to reach $1.1B by 2028, growing at a CAGR of 11.8% from 2023 to 2028, according to a MarketsandMarkets™report. “Smart pills” will enable remote patient monitoring, providing real-time data on physiological parameters and medication adherence. With imaging capabilities, they will ...
read more
Spanish-based nutraceuticals contractor development and manufacturing organization company SUANFARMA, which specializes in the development, production, and commercialization of ingredients, announced that Anthony Weston started as CEO of SUANNUTRA in June.
read more
The market size for prenatal vitamin supplements will grow by $237.81M by 2027 at an 8% CAGR, according to a projection by Technavio.
read more
Bristol Meyers Squibb announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
read more
The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company announced.
read more
Health Canada's approved XCOPRI™ (cenobamate tablets) for Paladin Labs, an Endo operating company. The medicine provides adjunctive therapy to manage partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
read more